Mineralys Therapeutics Inc
NASDAQ:MLYS
Cash Flow Statement
Cash Flow Statement
Mineralys Therapeutics Inc
| Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||
| Net Income |
(30)
|
(42)
|
(55)
|
(57)
|
(72)
|
(91)
|
(120)
|
(153)
|
(178)
|
(189)
|
(191)
|
(171)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Stock-Based Compensation |
0
|
1
|
2
|
4
|
5
|
7
|
8
|
10
|
11
|
13
|
14
|
17
|
|
| Other Non-Cash Items |
(0)
|
(0)
|
(1)
|
(1)
|
(2)
|
(2)
|
(1)
|
(0)
|
2
|
5
|
7
|
10
|
|
| Change in Working Capital |
1
|
1
|
(7)
|
(4)
|
(7)
|
6
|
24
|
25
|
10
|
(9)
|
(10)
|
(10)
|
|
| Cash from Operating Activities |
(29)
N/A
|
(42)
-44%
|
(62)
-49%
|
(62)
+0%
|
(81)
-30%
|
(87)
-7%
|
(97)
-11%
|
(128)
-32%
|
(166)
-30%
|
(193)
-16%
|
(193)
0%
|
(171)
+11%
|
|
| Investing Cash Flow | |||||||||||||
| Capital Expenditures |
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
|
| Other Items |
(22)
|
(162)
|
(178)
|
(102)
|
(160)
|
(76)
|
(52)
|
24
|
115
|
78
|
27
|
(203)
|
|
| Cash from Investing Activities |
(22)
N/A
|
(162)
-645%
|
(178)
-10%
|
(102)
+43%
|
(160)
-57%
|
(76)
+53%
|
(52)
+32%
|
24
N/A
|
115
+384%
|
78
-32%
|
27
-65%
|
(203)
N/A
|
|
| Financing Cash Flow | |||||||||||||
| Net Issuance of Common Stock |
130
|
333
|
333
|
203
|
203
|
115
|
116
|
116
|
117
|
190
|
200
|
495
|
|
| Other |
(2)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Cash from Financing Activities |
128
N/A
|
332
+159%
|
331
0%
|
202
-39%
|
203
+1%
|
115
-43%
|
116
+1%
|
116
0%
|
116
+0%
|
189
+63%
|
199
+5%
|
494
+148%
|
|
| Change in Cash | |||||||||||||
| Net Change in Cash |
77
N/A
|
128
+66%
|
90
-29%
|
37
-59%
|
(38)
N/A
|
(48)
-24%
|
(32)
+32%
|
11
N/A
|
65
+470%
|
75
+15%
|
33
-55%
|
120
+259%
|
|
| Free Cash Flow | |||||||||||||
| Free Cash Flow |
(29)
N/A
|
(42)
-44%
|
(62)
-49%
|
(62)
+0%
|
(81)
-30%
|
(87)
-8%
|
(97)
-11%
|
(128)
-32%
|
(166)
-30%
|
(193)
-16%
|
(193)
0%
|
(171)
+11%
|
|